WYNZORA (Betamethasone Dipropionate; Calcipotriene) Patent Expiration, LOE Window & CMS Spending
WYNZORA (Betamethasone Dipropionate; Calcipotriene) by Mc2 Therapeutics: FDA Orange Book core substance LOE 2039-03-18, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Mc2 Therapeutics |
| FDA Application & Pathway | N213422 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2039-03-18 |
| Last Listed Patent or Exclusivity Date | 2039-03-18 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 13.9% 2-yr change) |